N@N

Four Years After Covid-19 Success, mRNA Vaccines Aren't Ready for Bird Flu

The article discusses the challenges in developing mRNA vaccines for bird flu, despite the success of mRNA technology in combating COVID-19. Four years after the first mRNA vaccines were administered, the technology has not yet been adapted for bird flu due to several reasons. Firstly, there is less urgency and funding for bird flu vaccines since it primarily affects poultry and has not caused a widespread human outbreak. Secondly, the bird flu virus, particularly strains like H5N1, mutates rapidly, making it difficult to target with a vaccine that might become outdated quickly. Additionally, the logistics of producing, testing, and distributing an mRNA vaccine for bird flu are complex, involving not just scientific hurdles but also regulatory and economic considerations. While there is potential for mRNA vaccines to be effective against bird flu, the current focus and resources are not sufficiently directed towards this threat, leaving the world potentially unprepared for a bird flu pandemic.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/microbiology/four-years-after-covid-19-success-mrna-vaccines-aren-t-ready-for-bird-flu/ar-AA1xQgrx ]